Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05006131 · ClinicalTrials.gov registry record
Pancreatic Cancer Screening for At-risk Individuals
A clinical trial of Pancreatic Cancer, Adult, sponsored by Beth Israel Deaconess Medical Center.
- Recruiting
- Registry status
- 1,395
- Enrollment target
- 1
- Study location
NCT05006131: Recruiting study of Pancreatic Cancer, Adult, sponsored by Beth Israel Deaconess Medical Center.
NCT05006131 is a study of Pancreatic Cancer, Adult that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 1,395 participants, above the 46-participant average among 3 other Pancreatic Cancer, Adult trials with a reported enrollment target (2933% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05006131, a study of Pancreatic Cancer, Adult, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.
- RECRUITING
- Registry status
- 1,395 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators' goal is to conduct a prospective multicenter study to evaluate the yield and outcomes of screening of pancreas cancer in individuals who are at-risk for pancreatic cancer. We plan to use International Cancer of the Pancreas Screening (CAPS3) Consortium recommendations to standardize study population, screening methodology, and study outcomes.
Primary Outcome
Proportion of patients who meet CAPS 3 or updated national screening guidelines criteria who are found at screening to have high-risk pancreatic lesions amenable to treatment. These are defined as the following: 1. Lesions with high-grade dysplasia (HGD) 2. High-grade pancreatic intraepithelial neoplasia (PanIN) 3. Resectable or borderline resectable pancreatic cancer. Pancreatic cancers that were staged T1-3, N0-2, and M0 designated as resectable or borderline resectable. Cancers that were st
Conditions Studied
Interventions
- OTHER Screening for pancreatic cancer
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,395 participants |
| Start Date | 2020-07-10 |
| Est. Completion | 2032-12-31 |
What NCT05006131 shows while recruiting
NCT05006131 is an observational study that tracks outcomes without assigning an intervention. Its 1,395 participants enrollment target places it among the larger protocols in the corpus, above the 46-participant average among 3 other Pancreatic Cancer, Adult trials with a reported enrollment target (2933% higher).
The record links to 1 condition, with Pancreatic Cancer, Adult appearing as the primary indexed condition, and to 1 intervention - of which Screening for pancreatic cancer is the first listed.
NCT05006131 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05006131 about?
NCT05006131 is a clinical study titled "Pancreatic Cancer Screening for At-risk Individuals". The investigators' goal is to conduct a prospective multicenter study to evaluate the yield and outcomes of screening of pancreas cancer in individuals who are at-risk for pancreatic cancer. We plan to use International Cancer of the Pancreas Screening (CAPS3) Consortium recommendations to standardi...
What is the current status of trial NCT05006131?
This trial is currently recruiting. The enrollment target is 1,395 participants. The study started on 2020-07-10. Estimated completion is 2032-12-31.
What conditions does trial NCT05006131 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Adult.
What interventions are being tested in trial NCT05006131?
The interventions under investigation include: Screening for pancreatic cancer (OTHER).
Who is sponsoring clinical trial NCT05006131?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05006131 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine
ACTIVE NOT RECRUITING · Phase 1
-
Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02205762 · 1,400 participants · Phase 2
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
- NCT02445222 · 1,400 participants · Phase 3
CAR-T Long Term Follow Up (LTFU) Study
- NCT03145077 · 1,400 participants · NA
Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Diagnosing Osteoradionecrosis in Patients With Head and Neck Cancer That Is Primary, Has Come Back, or Has Spread to Other Places in the Body
- NCT04250857 · 1,400 participants
HeartStart FRx Defibrillator Event Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI